Prevention of type 1 diabetes: where we are and where we are going

التفاصيل البيبلوغرافية
العنوان: Prevention of type 1 diabetes: where we are and where we are going
المؤلفون: Giuseppe d'Annunzio, Andrea Scaramuzza, Sonia Toni, F. Citriniti, Salvatore Guercio Nuzio, Riccardo Bonfanti, Giulio Frontino
المساهمون: Frontino, G., Guercio, N. S., Scaramuzza, A., Annunzio, G. D., Toni, S., Citriniti, F., Bonfanti, R.
المصدر: Minerva Pediatrics. 73
بيانات النشر: Edizioni Minerva Medica, 2022.
سنة النشر: 2022
مصطلحات موضوعية: endocrine system, Pediatrics, medicine.medical_specialty, endocrine system diseases, Anti cd3, Antibodies, Monoclonal, Humanized, immune system diseases, Control, Diabetes Mellitus, medicine, Humans, Stage (cooking), Type 1 diabetes, Teplizumab, business.industry, Prevention, Incidence, Incidence (epidemiology), nutritional and metabolic diseases, medicine.disease, Diabetes Mellitus, Type 1, Chronic disease, Pediatrics, Perinatology and Child Health, Narrative review, business, Type 1, medicine.drug
الوصف: T1D (T1D) is one of the most frequent chronic disease in children and is associated to the risk of severe acute and chronic complications. There are about 550,000 children with T1D in the world; and about 86,000 children are diagnosed with T1D every year and its incidence is ever increasing. In this narrative review we will discuss current and future perspectives in T1D prevention strategies as well as their pitfalls. It is important to remember that for the first time one drug, in particular teplizumab (antibody anti-CD3) is going to be accepted for treatment in stage 2 of type 1 diabetes mellitus. This represent the onset of a new era.
تدمد: 2724-5780
2724-5276
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cb1bfe0887216a909ae83b6f4ffe8cfTest
https://doi.org/10.23736/s2724-5276.21.06529-0Test
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....3cb1bfe0887216a909ae83b6f4ffe8cf
قاعدة البيانات: OpenAIRE